바운드리스 바이오(BOLD)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.83 (+1.98%), 시가총액 $0.03B, 52주 범위 $1.01 ~ $1.66.
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San
바운드리스 바이오의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
바운드리스 바이오의 현재 주가는 $2.83 (+1.98%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
바운드리스 바이오의 시가총액은 약 $0.03B입니다.
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product c